Overview
- Lilly completed the purchase of Engage Biologics in a transaction announced on Wednesday that values the company at up to $202 million.
- The agreement pays an upfront cash sum with additional contingent payments tied to development milestones, moving risk and reward onto future progress.
- Engage’s Tethosome platform is a preclinical, non‑viral system that combines lipid nanoparticle delivery with mRNA‑encoded sequences to carry DNA payloads to target tissues.
- The acquisition is the latest step in Lilly’s broad genetic‑medicine buildout following multiple buys in 2025–2026, including Ajax, Kelonia, Centessa and Orna, as the company adds diverse delivery and therapeutic technologies.
- Because Tethosome remains preclinical, Lilly will first work to validate safety and efficacy in lab and animal studies before human trials, and the company will seek milestones that test whether the platform improves potency, patient tolerability and the ability to re‑dose compared with viral vectors.